A randomised controlled clinical trial to evaluate the anti-osteolytic agent clodronate for the prevention of the development of bone metastases in patients with primary breast cancer
Completed
- Conditions
- Breast cancerCancer
- Registration Number
- ISRCTN83688026
- Lead Sponsor
- Royal Marsden Hospital (UK), secondary sponsor Schering (Germany)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Female
- Target Recruitment
- 1000
Inclusion Criteria
Histologically or cytologically confirmed primary operable breast cancer with no evidence of metastases
Exclusion Criteria
1. Significant renal, hepatic or non-malignant bone disease
2. Previous history of malignant disease
3. Prior bisphosphonate use
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method